{"input_url":"https://insilico.com/news/034jeh2rl1-insilico-medicine-receives-fda-fast-trac","gnews_decode":"https://insilico.com/news/034jeh2rl1-insilico-medicine-receives-fda-fast-trac","http_status":200,"final_url":"https://insilico.com/news/034jeh2rl1-insilico-medicine-receives-fda-fast-trac","html_length":42608,"trafilatura_result":"ok","text_length":9402,"text_preview":"- FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico’s first FTD, recognizing the clinical potential in advanced mesothelioma.\n- ISM6331 is a novel, potential best-in-class, pan-TEAD inhibitor engineered via Chemistry42 to restore ","verdict":"OK"}